Crystal building blocks of triglycerides
Francis Crick once said, “If you want to understand function, study structure.” Do you agree? I certainly do, and I would argue that most lipid biologists do too. Just consider the effort to define chemical structures for the many thousands of lipids that exist and the hypotheses about individual lipid function that this structural information has generated.
What has lagged behind is the characterization of the structures of the proteins that modify, transport or interact with these lipids, but times are changing. For example, when I started my postdoc in lab, only a handful of sphingolipid-metabolizing enzymes had been structurally characterized, and these were mainly from bacteria. While many questions remain open (hey, ceramide synthase — we can’t wait to see what you look like!), work from several labs has defined the structures and mechanisms for many human enzymes in sphingolipid metabolism.
A similar revolution appears to be happening with triglycerides. As most of you know, triglycerides serve as a reservoir for energy storage, but when they accumulate excessively, they can cause health problems, including obesity, diabetes and heart disease. Three new structures in particular have caught my attention.
Beautiful structures of proteins involved in triglyceride metabolism and storage.Michael Airola is a crystal structure of microsomal triglyceride transfer protein complex, which transfers neutral lipids into apolipoprotein B-containing lipoproteins. The arduous crystallography required to conduct this work is impressive. The researchers revealed an unexpected lipid-binding cavity and provided insight into disease mutations as well as pharmacological inhibition of this therapeutic target.
The second is the crystal structure of lipoprotein lipase, or LPL, the major lipase that clears triglycerides in the blood. and separately determined the LPL structures, overcoming the relative instability of LPL by complexing it with its binding partner glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. These structures, along with other biochemical data, suggest LPL is active as a monomer, challenging the long-standing paradigm that LPL was only active as a dimer.
The last notable structure is that of seipin, a homo-oligomeric integral membrane protein that is a key player in the formation of cytoplasmic lipid droplets. Two groups ( and ), using cryo-electron microscopy, found that 11 or 12 seipin molecules (dependent on the species) come together to form a ring that spans the endoplasmic reticulum membrane, can bind phosphatidic acid and may stabilize the formation of nascent lipid droplets.
What’s next? Who knows, but I’m darn sure we’re all gonna love it.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬÀï·¬ paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ɬÀï·¬ paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.